LFST vs LMAT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LFST presents a stable but precarious financial profile with a Piotroski F-Score of 4/9 and no Altman Z-Score provided for bankruptcy risk assessment. While the company has successfully transitioned toward profitability with a promising forward P/E of 16.74, it trades at a massive premium compared to its Graham Number ($1.33) and Intrinsic Value ($0.14). Strong revenue growth of 17.4% is offset by razor-thin profit margins (0.68%) and aggressive insider selling totaling $32.51M. The stock is currently a speculative play on earnings expansion rather than a value-driven investment.
LMAT exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and exceptional liquidity, but it is currently facing a severe valuation disconnect. While the company shows strong growth (41.4% earnings growth) and high gross margins, the current price of $114.62 significantly exceeds both the Graham Number ($31.3) and the growth-based Intrinsic Value ($74.34). This premium is further complicated by heavy insider selling, including a large divestment by the CEO, and a bearish technical trend despite the price being near 52-week highs.
Compare Another Pair
Related Comparisons
LFST vs LMAT: Head-to-Head Comparison
This page compares LifeStance Health Group, Inc. (LFST) and LeMaitre Vascular, Inc. (LMAT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.